Highly Efficient Olefin-Metathesis Catalysts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Highly Efficient Olefin-Metathesis Catalysts
The authors describe the Piers' catalysts and detail latest progress in olefin-metathesis catalyst technology.


Pharmaceutical Technology



Figure 5 (ALL FIGURES ARE COURTESY OF THE AUTHORS.)
Two recent, excellent examples of olefin metathesis from the Stoltz group demonstrate the usefulness of Catalyst 6 (see Figure 5) for natural-product synthesis. Catalyst 6 was successfully used for a key RCM step in the synthesis of elatol, a natural product from chamigrene, which has broad antimicrobial activity (21). In another recent example, the Stoltz group reported the synthesis of (–)–Cyanthiwigin F where Catalyst 6 completed both a RCM and CM step in the same reaction flask (22).

The metathesis catalysts shown in Figures 4 and 5 are typical 5-coordinate ruthenium olefin-metathesis catalysts. The first step in the metathesis reaction involving these catalysts is the dissociation of the donor ligand trans to the phosphine or the N -heterocyclic carbene ligand , generating the catalytically active 4-coordinate, 14-electron species. This 14-electron species binds an olefin, forms a metallocyclobutane ring, and productively undergoes a cycloreversion to yield the new olefinic product. Efficient dissociation of the donor ligand and olefin binding are key for fast initiation of these catalysts.

Piers' catalysts are another new addition to the ruthenium olefin-metathesis catalyst family. Piers' catalysts adopt a pseudo-tetrahedral geometry and possess an open coordination site trans to the phosphine (see Catalyst 1, Figure 1) or the N -heterocyclic carbene ligand (see Catalyst 2, Figure 1) (6, 7). This open coordination site eliminates the need for any ligand dissociation prior to olefin coordination. As such, olefin binding and activation is anticipated to be more facile with Piers' catalysts.

Catalysts 1 and 2 are highly active for the metathesis of terminal olefins. For example, Catalyst 2a reacts with ethylene at –50 C (8). Kinetic studies on the initiation of metathesis with o –isopropoxystyrene as a test substrate indicated that the initiation rate of Catalyst 2a (see Figure 1) at –10 C is similar to the initiation rate of the Grubbs catalyst (see Catalysts 3 and 4, Figure 4) at 35 C (6). Piers' catalysts offer the additional advantage of running metathesis reactions at lower temperatures when the substrates may be temperature sensitive or to suppress double-bond migration.

Use of Piers' olefin-metathesis catalysts

The Piers' group is developing these novel catalysts and, along with Materia, is exploring their use for a range of industrial applications, including ethenolysis, RCM, CM, self-metathesis, and ring-opening metathesis polymerization (ROMP). In general, Catalysts 1 and 2 (see Figure 1) are more active than the Grubbs catalysts (see Catalysts 3 and 4, Figure 4) for the metathesis of terminal olefins. In addition, Piers' catalysts are very active at low temperatures, and thus, are of interest to those applications where low temperatures are desired. Not too surprising, Catalysts 1 and 2 are somewhat slower for metathesis reactions involving only internal olefins such as the CM of internal olefins, which is likely due to the steric bulk of the cationic PCy3 alkylidene moiety (23).


Reaction 1
The high efficiency of Piers' catalysts for metathesis involving ethylene and other terminal olefins is particularly valuable for the industrially significant ethenolysis and RCM reactions described below.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here